Critics and eating disorder specialists express deep concern that the promotion of GLP-1 receptor agonists for eating disorders could be dangerous, potentially worsening the very conditions they are meant to treat. Because these medications are designed to suppress appetite and induce rapid weight loss, they risk reinforcing the restrictive behaviors and body-image obsessions that are central to eating disorder pathology. For individuals already struggling with a distorted relationship with food, the promise of a 'quick fix' can be a powerful and harmful trigger.
There is also significant alarm regarding the current landscape of access. With the rise of online pharmacies and private clinics, there is a real risk that these powerful hormones could be prescribed without the necessary psychological assessment or multidisciplinary oversight. Experts from organizations like the Royal College of Psychiatrists have previously warned that framing these drugs as universal weight-loss aids can validate harmful cultural messages about body size, making it harder for those in recovery to maintain a healthy, intuitive relationship with food.
Ultimately, the concern is that these drugs treat the symptom—weight or overeating—rather than the underlying mental health condition. By interfering with the body's natural hunger cues, these medications may prevent patients from learning the essential skills needed for long-term recovery. Until there is robust evidence that these drugs can be used safely without exacerbating psychological distress, the medical community must prioritize caution and ensure that eating disorder screening remains a mandatory, non-negotiable part of any clinical assessment involving these medications.